Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Clinical Trials in Taiyuan, Shanxi

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm